Perrigo (NYSE:PRGO) Releases Earnings Results, Beats Expectations By $0.19 EPS

Perrigo (NYSE:PRGO) announced its quarterly earnings data on Wednesday. The company reported $0.50 earnings per share for the quarter, beating analysts’ consensus estimates of $0.31 by $0.19, FiscalAI reports. The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.02 billion. Perrigo had a negative net margin of 41.85% and a positive return on equity of 11.25%. The company’s revenue for the quarter was down 3.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.06) EPS. Perrigo updated its FY 2026 guidance to 2.250-2.550 EPS.

Here are the key takeaways from Perrigo’s conference call:

• Market share gains continued despite weak categories: U.S. store-brand OTC volumes grew 1.5% and gained 50 basis points of share, while European key brands grew 3.3% and also gained 50 basis points.
• Perrigo reaffirmed its full-year 2026 outlook, citing improving category trends, innovation and distribution gains, operational savings, and lower interest expense following debt repayment.
• Q2 core net sales fell 3.1% and core adjusted EPS declined to $0.46, while core adjusted gross margin dropped 250 basis points to 37%. Results benefited from approximately $10 million in tariff recoveries and a $6 million CEO-transition benefit, limiting the significance of the earnings beat.
• The company applied most of the $359 million Dermacosmetics sale proceeds to debt reduction, lowering its revolving credit balance, while its operational enhancement program remains on track to generate $80 million–$100 million in savings by 2027.
• Strategic reviews of the infant formula and oral care businesses are progressing, with Perrigo considering optimization, partnerships, or divestitures; management said improved infant-formula performance provides greater optionality but does not alter the review process.

Perrigo Price Performance

Shares of PRGO stock traded up $0.33 during mid-day trading on Friday, hitting $12.87. 1,127,494 shares of the stock traded hands, compared to its average volume of 3,210,413. Perrigo has a twelve month low of $9.23 and a twelve month high of $24.60. The firm has a market cap of $1.78 billion, a price-to-earnings ratio of -1.03, a price-to-earnings-growth ratio of 1.38 and a beta of 0.51. The company’s 50-day simple moving average is $10.58 and its 200-day simple moving average is $11.53. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.59 and a current ratio of 2.32.

Perrigo Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Friday, August 28th will be given a $0.29 dividend. This represents a $1.16 dividend on an annualized basis and a yield of 9.0%. The ex-dividend date is Friday, August 28th. Perrigo’s dividend payout ratio is -8.85%.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on PRGO. Zacks Research upgraded Perrigo from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Weiss Ratings upgraded Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 21st. One research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $19.33.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. UMB Bank n.a. grew its stake in shares of Perrigo by 161.5% in the 4th quarter. UMB Bank n.a. now owns 1,964 shares of the company’s stock worth $27,000 after purchasing an additional 1,213 shares during the last quarter. Geneos Wealth Management Inc. boosted its holdings in Perrigo by 439.1% during the first quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock worth $27,000 after buying an additional 786 shares in the last quarter. Meeder Asset Management Inc. acquired a new position in Perrigo in the fourth quarter worth approximately $28,000. Kestra Investment Management LLC grew its position in Perrigo by 57.1% in the second quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock worth $47,000 after buying an additional 642 shares during the last quarter. Finally, Danske Bank A S bought a new position in shares of Perrigo in the third quarter valued at $53,000. Institutional investors own 95.91% of the company’s stock.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.